SecBot SecBot
8-K ·Filed Sep 1, 2026

MDT

Medtronic plc
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001628280-26-059697
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The guidance raise and broad-based organic growth acceleration (13.7% vs 5.8% FY26 full-year) signal improving operational momentum. Watch for continued Cardiac Ablation Solutions share gains and Diabetes separation catalyst. The extra week benefit (~$570M) is a one-time factor, but underlying trends remain strong.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Medtronic reported Q1 FY27 revenue of $9.756B (+13.7% organic, ~200bps above guidance midpoint) and non-GAAP EPS of $1.45, ahead of consensus. The company raised FY27 organic revenue growth guidance to 7.25%-7.75% (from 6.75%-7.25%) and EPS guidance to $5.94-$6.00. Broad-based strength across Cardiovascular (+18.9% organic), Neuroscience (+9.3%), Medical Surgical (+10.2%), and Diabetes (+14.9%) drove the beat. The extra fiscal week contributed ~$570M to organic growth, but the guidance raise and strong execution signal durable momentum.

Key Financial Metrics

EPS
$1.45
est $1.39 · +4.3%
Revenue
$9.8B
est $9.5B · +2.3% · +13.7% YoY
Rating
strong beat
Guidance
7.25%-7.75% organic growth
raised
Free Cash Flow
$1.3B
Gross Margin
65%

Key Facts

  • Revenue of $9.756B, +13.7% as reported and +13.7% organic, ~200bps above guidance midpoint
  • Non-GAAP diluted EPS of $1.45, ahead of consensus estimate of $1.39
  • Raised FY27 organic revenue growth guidance to 7.25%-7.75% (from 6.75%-7.25%)
  • Raised FY27 non-GAAP EPS guidance to $5.94-$6.00 (from $5.90-$6.00)
  • Cardiovascular grew 18.9% organic, led by Electrophysiology Therapies +29.1%
  • Neuroscience grew 9.3% organic, Medical Surgical +10.2%, Diabetes +14.9%
  • GAAP operating margin expanded 120bps to 18.1%; non-GAAP operating margin +10bps to 23.7%
  • Free cash flow of $1.290B, more than doubled from $584M in prior-year Q1
  • Extra fiscal week benefited Q1 organic growth by ~$570M

Financial Impact

Revenue beat consensus by ~$216M (2.3%); EPS beat consensus by $0.06 (4.3%). Guidance raise implies ~$200M+ incremental FY27 revenue at midpoint.

revenueepsoperating marginfree cash flow

Risk Factors

  • Extra fiscal week (~$570M) inflated Q1 organic growth; underlying run-rate is lower
  • Non-GAAP operating margin only +10bps despite strong revenue growth, indicating cost pressures
  • Diabetes separation structure (split-off vs spin-off) remains undecided, creating execution uncertainty
  • Tariff and MiniMed Blackstone payment headwinds (~50bps and ~45bps respectively in FY26) persist

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
65% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-059697
Document: mdt-20260901.htm0001628280-26-059697
Document: 0001628280-26-059697-index-headers.html0001628280-26-059697
Document: 0001628280-26-059697-index.html0001628280-26-059697
Document: 0001628280-26-059697.txt0001628280-26-059697
8-K Data (Synthetic)0001628280-26-059697

Track record

53 reports on MDT

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.30% at T+60 after the Jun 3, 2026 report. 9 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
  4. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
  5. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  6. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  7. Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
  8. Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  9. Oct 14, 20264w ago 425 Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  10. Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026